BioRestorative Therapies (BRTX)

Executive Summary

BioRestorative Therapies is a clinical-stage biotechnology company developing stem cell-based therapies for chronic degenerative conditions. Its lead program, BRTX-100, is an autologous cell therapy for chronic lumbar disc disease currently in a Phase 2 trial (NCT04042844) with an expected completion date of December 2027. The company's pipeline also includes ThermoStem, a preclinical program for metabolic disorders like obesity and diabetes, and a commercial BioCosmeceuticals platform that markets stem cell-derived biologics for aesthetic applications. With a low valuation (~$5.5M) and a Phase 2 asset targeting a large unmet need in disc disease, BioRestorative offers a high-risk, high-reward opportunity. The company is publicly traded (BRTX) and has limited near-term revenue, relying on successful trial data and potential partnerships to drive value.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 interim data readout for BRTX-10040% success
• Q4 2026Enrollment completion of Phase 2 trial for BRTX-10070% success
• Q1 2027Preclinical or IND-enabling update for ThermoStem program30% success